Calliditas Therapeutics AB (publ) (CALT)

Market Cap	1.04B
Revenue (ttm)	119.73M
Net Income (ttm)	-46.25M
Shares Out	26.84M
EPS (ttm)	-1.64
PE Ratio	n/a
Forward PE	18.38
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,604
Open	38.60
Previous Close	38.43
Day's Range	38.50 - 38.75
52-Week Range	15.25 - 41.90
Beta	1.57
Analysts	Hold
Price Target	37.50 (-3.23%)
Earnings Date	Aug 15, 2024

About CALT

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical tr...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 5, 2020
• Employees: 219
• Stock Exchange: NASDAQ
• Ticker Symbol: CALT

Financial Performance

In 2023, CALT's revenue was 1.21 billion, an increase of 50.32% compared to the previous year's 802.88 million. Losses were -466.19 million, 13.1% more than in 2022.

Financial numbers in SEK

Analyst Forecast

According to 6 analysts, the average rating for CALT stock is "Hold." The 12-month stock price forecast is $37.5, which is a decrease of -3.23% from the latest price.

Price Target

$37.5

(-3.23% downside)

Analyst Consensus: Hold